Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC.MDGL · Entity 3441 | Chief Commercial Officer | March 04, 2026 | March 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MADRIGAL PHARMACEUTICALS, INC.
Report date March 04, 2026 · Filed March 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,692 |
Ending reported balance
After 2026-03-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-04 · Grant · Acquired 3,989 · Balance 13,111 F1: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030, provided the Reporting Person continues in service with the Issuer on each such date. Row 2 · 2026-03-06 · Sale · Disposed 419 · Balance 12,692 F2: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $434.80 · Expires 2036-03-04 | Direct | 4,986 |
Reported balance
After 2026-03-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-03-04 · Grant · Acquired 4,986 · Balance 4,986 F3: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 4, 2027) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030, provided the Reporting Person continues in service with the Issuer on each such date.
F2: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.
F3: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 4, 2027) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 06, 2026 Filed Mar 6, 2026 23:15 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 419 | $431.94 | $180,982.86 |
DisclosureSEC source: 0001628280-26-015758 · wk-form4_1772838950.xml · nonDerivative · entry 2 Huntsman Carole · CIK 0002001571 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,692 F2 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:15 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 4,986 | $0.00 Strike: $434.80 | $0.00 |
DisclosureSEC source: 0001628280-26-015758 · wk-form4_1772838950.xml · derivative · entry 3 Huntsman Carole · CIK 0002001571 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,986 Underlying: Common Stock · 4,986 shares Expires 2036-03-04 F3 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 4, 2027) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:15 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantCommon Stock | 3,989 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-015758 · wk-form4_1772838950.xml · nonDerivative · entry 1 Huntsman Carole · CIK 0002001571 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,111 F1 · kind: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| January 26, 2026 Filed Jan 26, 2026 22:38 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 570 | $494.59 | $281,916.30 |
DisclosureSEC source: 0001628280-26-003482 · wk-form4_1769467117.xml · nonDerivative · entry 2 Huntsman Carole · CIK 0002001571 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,122 F2 · kind: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024. Read SEC document |
| January 26, 2026 Filed Jan 26, 2026 22:38 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 340 | $492.42 | $167,422.80 |
DisclosureSEC source: 0001628280-26-003482 · wk-form4_1769467117.xml · nonDerivative · entry 1 Huntsman Carole · CIK 0002001571 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,692 F1 · kind: The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. Read SEC document |
| November 21, 2025 Filed Nov 21, 2025 22:39 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 80 | $564.57 | $45,165.20 |
DisclosureSEC source: 0001628280-25-053648 · wk-form4_1763764773.xml · nonDerivative · entry 11 Huntsman Carole · CIK 0002001571 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,032 F2 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $564.55 to $564.58, inclusive. Read SEC document |
| November 21, 2025 Filed Nov 21, 2025 22:39 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 40 | $563.21 | $22,528.40 |
DisclosureSEC source: 0001628280-25-053648 · wk-form4_1763764773.xml · nonDerivative · entry 10 Huntsman Carole · CIK 0002001571 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,112 F2 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024. Read SEC document |
| November 21, 2025 Filed Nov 21, 2025 22:39 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 80 | $560.62 | $44,849.60 |
DisclosureSEC source: 0001628280-25-053648 · wk-form4_1763764773.xml · nonDerivative · entry 9 Huntsman Carole · CIK 0002001571 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,152 F2 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $560.24 to $561.00, inclusive. Read SEC document |
| November 21, 2025 Filed Nov 21, 2025 22:39 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 200 | $559.60 | $111,919.60 |
DisclosureSEC source: 0001628280-25-053648 · wk-form4_1763764773.xml · nonDerivative · entry 8 Huntsman Carole · CIK 0002001571 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,232 F2 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $559.22 to $560.06, inclusive. Read SEC document |
| November 21, 2025 Filed Nov 21, 2025 22:39 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 120 | $556.04 | $66,724.80 |
DisclosureSEC source: 0001628280-25-053648 · wk-form4_1763764773.xml · nonDerivative · entry 7 Huntsman Carole · CIK 0002001571 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,432 F2 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $555.74 to $556.19, inclusive. Read SEC document |
| November 21, 2025 Filed Nov 21, 2025 22:39 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 40 | $553.23 | $22,129.13 |
DisclosureSEC source: 0001628280-25-053648 · wk-form4_1763764773.xml · nonDerivative · entry 6 Huntsman Carole · CIK 0002001571 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,552 F2 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $553.22 to $553.23, inclusive. Read SEC document |
| November 21, 2025 Filed Nov 21, 2025 22:39 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 200 | $552.38 | $110,476.80 |
DisclosureSEC source: 0001628280-25-053648 · wk-form4_1763764773.xml · nonDerivative · entry 5 Huntsman Carole · CIK 0002001571 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,592 F2 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $551.96 to $552.81, inclusive. Read SEC document |
| November 21, 2025 Filed Nov 21, 2025 22:39 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 40 | $549.34 | $21,973.70 |
DisclosureSEC source: 0001628280-25-053648 · wk-form4_1763764773.xml · nonDerivative · entry 4 Huntsman Carole · CIK 0002001571 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,792 F2 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $549.30 to $549.38, inclusive. Read SEC document |
| November 21, 2025 Filed Nov 21, 2025 22:39 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 120 | $548.71 | $65,845.20 |
DisclosureSEC source: 0001628280-25-053648 · wk-form4_1763764773.xml · nonDerivative · entry 3 Huntsman Carole · CIK 0002001571 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,832 F2 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $548.25 to $548.94, inclusive. Read SEC document |
| November 21, 2025 Filed Nov 21, 2025 22:39 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 144 | $547.27 | $78,806.64 |
DisclosureSEC source: 0001628280-25-053648 · wk-form4_1763764773.xml · nonDerivative · entry 2 Huntsman Carole · CIK 0002001571 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,952 F2 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $547.12 to $547.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. Read SEC document |
| November 21, 2025 Filed Nov 21, 2025 22:39 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 894 | $550.97 | $492,567.18 |
DisclosureSEC source: 0001628280-25-053648 · wk-form4_1763764773.xml · nonDerivative · entry 1 Huntsman Carole · CIK 0002001571 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,096 F1 · kind: The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:31 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 5,703 | $0.00 Strike: $347.28 | $0.00 |
DisclosureSEC source: 0001628280-25-011321 · wk-form4_1741383098.xml · derivative · entry 2 Huntsman Carole · CIK 0002001571 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,703 Underlying: Common Stock · 5,703 shares Expires 2035-03-05 F2 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 5, 2026) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:31 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantCommon Stock | 3,386 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-011321 · wk-form4_1741383098.xml · nonDerivative · entry 1 Huntsman Carole · CIK 0002001571 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,990 F1 · kind: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 5, 2026, March 5, 2027, March 5, 2028 and March 5, 2029, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:24 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 563 | $335.00 | $188,605.00 |
DisclosureSEC source: 0001628280-25-010492 · wk-form4_1741209863.xml · nonDerivative · entry 9 Huntsman Carole · CIK 0002001571 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,604 F1 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:24 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 100 | $329.64 | $32,964.00 |
DisclosureSEC source: 0001628280-25-010492 · wk-form4_1741209863.xml · nonDerivative · entry 8 Huntsman Carole · CIK 0002001571 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,167 F1 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:24 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 100 | $327.49 | $32,749.00 |
DisclosureSEC source: 0001628280-25-010492 · wk-form4_1741209863.xml · nonDerivative · entry 7 Huntsman Carole · CIK 0002001571 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,267 F1 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:24 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 100 | $326.34 | $32,634.00 |
DisclosureSEC source: 0001628280-25-010492 · wk-form4_1741209863.xml · nonDerivative · entry 6 Huntsman Carole · CIK 0002001571 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,367 F1 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:24 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 200 | $324.59 | $64,918.00 |
DisclosureSEC source: 0001628280-25-010492 · wk-form4_1741209863.xml · nonDerivative · entry 5 Huntsman Carole · CIK 0002001571 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,467 F1 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $324.48 to $324.70, inclusive. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:24 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 200 | $323.65 | $64,730.00 |
DisclosureSEC source: 0001628280-25-010492 · wk-form4_1741209863.xml · nonDerivative · entry 4 Huntsman Carole · CIK 0002001571 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,667 F1 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $323.47 to $323.83, inclusive. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:24 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 300 | $320.21 | $96,063.00 |
DisclosureSEC source: 0001628280-25-010492 · wk-form4_1741209863.xml · nonDerivative · entry 3 Huntsman Carole · CIK 0002001571 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,867 F1 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $320.13 to $320.32, inclusive. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:24 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 200 | $314.74 | $62,948.00 |
DisclosureSEC source: 0001628280-25-010492 · wk-form4_1741209863.xml · nonDerivative · entry 2 Huntsman Carole · CIK 0002001571 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,167 F1 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $314.40 to $315.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:24 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 71 | $313.08 | $22,228.68 |
DisclosureSEC source: 0001628280-25-010492 · wk-form4_1741209863.xml · nonDerivative · entry 1 Huntsman Carole · CIK 0002001571 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,367 F1 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024. Read SEC document |
| January 24, 2025 Filed Jan 27, 2025 22:18 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 347 | $335.24 | $116,328.28 |
DisclosureSEC source: 0001628280-25-002680 · wk-form4_1738016309.xml · nonDerivative · entry 1 Huntsman Carole · CIK 0002001571 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,438 F1 · kind: The sale reported on this Form 4 represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. Read SEC document |
| November 21, 2024 Filed Nov 22, 2024 21:30 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 688 | $316.92 | $218,040.96 |
DisclosureSEC source: 0000950170-24-130239 · ownership.xml · nonDerivative · entry 1 Huntsman Carole · CIK 0002001571 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,785 F1 · kind: The sale reported on this Form 4 represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 23:04 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantMarket Stock Unit · Derivative | 3,639 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-007572 · ownership.xml · derivative · entry 3 Huntsman Carole · CIK 0002001571 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,639 Underlying: Common Stock · 3,639 shares Expires not disclosed F3 · derivative.exercise_price: Each market stock unit, which is performance-based, represents the contingent right to receive one share of common stock. The amount reported represents the target number of shares which may be issued upon vesting. The market stock units will vest upon certification concerning the Company's stock price performance measured against biotechnology stock index companies for the entire performance period ending December 31, 2026. F3 · derivative.exercise_date: Each market stock unit, which is performance-based, represents the contingent right to receive one share of common stock. The amount reported represents the target number of shares which may be issued upon vesting. The market stock units will vest upon certification concerning the Company's stock price performance measured against biotechnology stock index companies for the entire performance period ending December 31, 2026. F3 · derivative.expiration_date: Each market stock unit, which is performance-based, represents the contingent right to receive one share of common stock. The amount reported represents the target number of shares which may be issued upon vesting. The market stock units will vest upon certification concerning the Company's stock price performance measured against biotechnology stock index companies for the entire performance period ending December 31, 2026. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 23:04 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 5,483 | $0.00 Strike: $229.00 | $0.00 |
DisclosureSEC source: 0000950170-24-007572 · ownership.xml · derivative · entry 2 Huntsman Carole · CIK 0002001571 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,483 Underlying: Common Stock · 5,483 shares Expires 2031-01-23 F2 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (January 23, 2025) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 23:04 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantCommon Stock | 3,639 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-007572 · ownership.xml · nonDerivative · entry 1 Huntsman Carole · CIK 0002001571 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,473 F1 · kind: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 23, 2025, January 23, 2026, January 23, 2027 and January 23, 2028, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 22:02 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 10,077 | $0.00 Strike: $190.05 | $0.00 |
DisclosureSEC source: 0000950170-23-065902 · ownership.xml · derivative · entry 2 Huntsman Carole · CIK 0002001571 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,077 Underlying: Common Stock · 10,077 shares Expires 2033-11-20 F2 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (November 20, 2024) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 22:02 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantCommon Stock | 7,834 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-065902 · ownership.xml · nonDerivative · entry 1 Huntsman Carole · CIK 0002001571 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,834 F1 · kind: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of November 20, 2024, November 20, 2025, November 20, 2026 and November 20, 2027, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.